Tandem Diabetes Care Inc (NASDAQ:TNDM) Q2 2020 Earnings Conference Call - Final Transcript
Jul 30, 2020 • 04:30 pm ET
Ladies and gentlemen, thank you for standing by and welcome to Tandem's Second Quarter 2020 Earnings Call. [Operator Instructions]
I would now like to hand the conference over to your host, EVP and Chief Administrative Officer, Susan Morrison. Ma'am, please go ahead.
Great. Thank you, and welcome, everyone, to Tandem's second quarter 2020 earnings call.
Today's discussion will include forward-looking statements. These statements reflect management's expectations about future events, product development time lines and financial performance and operating plans and speak only as of today's date. There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements. A list of factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is highlighted in our press release issued earlier today and under the risk factors portion and elsewhere in our most recent annual report on Form 10-K, quarterly report on Form 10-Q and in our other SEC filings. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or other factors.
In addition, today's discussion will include references to adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is a key measure used by us to evaluate operating performance, generate future operating plans and make strategic decisions for the allocation of capital. Please refer to our press release issued earlier today for further information.
John Sheridan, President and CEO; and Leigh Vosseller, Executive Vice President and Chief Financial Officer will be participating on today's call. Following our prepared remarks, we'll open up the call for questions. Thanks for limiting yourself to asking two questions before getting back into the queue.
With that, I'll now turn the call over to John.
John F. Sheridan
Thanks, Susan, and good afternoon everyone and welcome to today's call. Looking back at the first half of 2020, the broader issues impacting the world continue to be at the forefront of our minds. Incredibly even in this challenging global environment, our business has excelled in its commercial, operational and strategic performance. I'd like to say a special thanks to our employees for their steadfast focus and commitment to improving the lives of people living with diabetes. It is only through their hard work and dedication that our customers are able to succeed and as a result so is our business. I am very proud of the team and all that we have accomplished. I'd also like to extend the continued thanks to the healthcare providers supporting the diabetes community and to the frontline workers, looking after all of us during these challenging times, in addition to all of our suppliers who continue to support us without disruption, thank you to everyone.
Next, I'd like to take a moment to extend an extra welcome to our two new board members, Kathleen McGroddy-Goetz and Peyton Howell. Kathy has extensive experience commercializing pioneering technologies that span from microelectronics through software, advanced data